Facial Fat Grafting vs Dermal Filler
以下の事実はすべて2つのエンティティページとその出典に基づきます。両方に記録のある項目を先に対比し、残りは並べて表示します。
医療
Facial Fat GraftingFacial fat grafting transfers the patient's own fat to the face to restore volume in areas such as the cheeks, temples and under-eye region.更新 2026年9月20日製品
Dermal FillerDermal fillers are injectable gels, most commonly hyaluronic acid, used to add volume or smooth lines in the face; effects are temporary.更新 2026年9月20日両者の関係Facial Fat Grafting — 代替 → Dermal Filler
共通項目
両側に記録あり 2件| 項目 | Facial Fat Grafting | Dermal Filler |
|---|---|---|
| Procedure steps | Fat is taken from a donor area by liposuction, decanted, centrifuged or otherwise processed, and the purified fat is reinjected where volume is needed | An injectable implant (soft tissue, lip, facial or wrinkle filler) used to make skin look smoother or fuller |
| US FDA tissue regulation | Exempt from 21 CFR Part 1271 when tissue is removed from and reimplanted into the same individual during the same surgical procedure (21 CFR 1271.15(b)) | Class III medical device that needs premarket approval (PMA); FDA product codes LMH (face) and PKY (back of hand) |
それぞれの事実
どちらか一方にのみ記録されている検証済みの事実です。
Facial Fat Grafting
First documented fat graft1893: Gustav Neuber moved fat from the arm to correct scarring around the eye
Standardized techniqueSydney Coleman published standardized protocols for harvesting, processing and injecting fat (structural fat grafting) in the 1990s
Common facial usesFilling hollows under the eyes and nasolabial folds, repairing scars, enhancing the cheekbones, improving skin texture
Typical total facial graft volume10–100
Reported arterial embolism outcomesIn 61 published cases: permanent vision loss in all 26 with ophthalmic artery occlusion, neurological impairment in 8 of 10 with cerebral artery occlusion, and 6 deaths
No reversal agentHyaluronic acid filler can be dissolved with hyaluronidase, but no agent of comparable effect exists for fat emboli
Worldwide facial fat grafting procedures589,494 procedures; 7th most common aesthetic surgical procedure (ISAPS Global Survey 2021, as cited)
AlternativeDermal fillers (temporary, non-surgical)
Specific riskVascular occlusion when injecting near the eyes or nose (rare)
Dermal Filler
Minimum approved age (US)22
Materials in FDA-approved fillersMostly bacterial-source cross-linked hyaluronic acid; also calcium hydroxylapatite and poly-L-lactic acid
Newer US-approved indicationsInfraorbital hollowing, jawline and temple, in addition to lips, cheeks, perioral lines and nasolabial folds (approvals are product-specific)
Uses not approved by the FDAInjectable silicone for any cosmetic use; breast or buttock augmentation; needle-free injectors; over-the-counter sale
Most serious riskAccidental injection into a blood vessel, which can cause skin necrosis, blindness or stroke; rare but possibly permanent
Reversal agent (HA fillers only)Hyaluronidase, used off-label to break down HA nodules, excess filler and vascular complications
Evidence for hyaluronidase in vascular occlusionNo RCTs or clinical trials; evidence is limited to retrospective case series (the review itself is rated Level III)
DurationTemporary; repeat treatments needed